ibrutinib,tisagenlecleucel
abbvie,novartis,janssen
[' ibru', 'mantle,(-dismantle)', 'lymsm', 'lymphoma', 'tisagenlecleucel']
combination ibrutinib and tisagenlecleucel produced an overall response rate of 85% in relapsed/refractory mantle cell lymphoma. #ash22 #lymsm #mcl 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.